Atrial fibrillation (AF) and atrial flutter (AFL) are increasingly prevalent cardiac arrhythmias that contribute to high mortality and morbidity, especially in the elderly population. Oral anticoagulants (OACs) remains the standard of care for stroke risk reduction in patients with non-valvular AF (NVAF) however there exists uncertainty amongst clinical decision makers for initiation in particular patients cohorts. This is frequently encountered for older adults where the net clinical benefit can be indeterminate in the context of considerations such as limited life expectancy, significant burden of comorbidities, and frailty syndrome [1]
